Nana Xu1,2, Qiao Zhang1,2, Guolan Wu1,2, Duo Lv1,2, Yunliang Zheng1,2. 1. Research Center of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China. 2. Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Abstract
BACKGROUND: Vancomycin is the standard therapy for methicillin-resistant Staphylococcus aureus (MRSA) infection; however, nephrotoxicity happened with a high incidence of 15%~40%. Weighting the risk before receiving vancomycin treatment facilitates timely prevention of nephrotoxicity, but no standardized strategy exists for this purpose. METHODS: A retrospective cohort study was performed. A total of 524 hospitalized patients treated with vancomycin were included in this study. They were divided into derivation cohort (n=341) and externally validation cohort (n=183) according to their admission time. Using univariate and multivariable logistic regression, we identified potential predictors of vancomycin-associated acute kidney injury (AKI) and developed a risk score by plotting nomogram. The predictive performance of this novel risk score was assessed and validated by discrimination and calibration. Besides, the risk score was also compared with existing prediction models according to integrated discrimination index (IDI) and net reclassification index (NRI). RESULTS: The incidence of AKI was 16.1% (55/341) in the derivation cohort and 16.4% (30/183) in the validation cohort. Three factors (vancomycin serum trough concentration, piperacillin/tazobactam and furosemide) were determined as predictors for vancomycin-associated AKI. The established three-item risk score showed a comparable discrimination in both derivation cohort (AUC=0.793, 95% CI: 0.732-0.855) and validation cohort (AUC=0.788, 95% CI: 0.698-0.877). The risk score also demonstrated a good calibration in the derivation cohort (χ 2=6.079, P=0.638>0.05) and validation cohort (χ2=5.665, P=0.686>0.05). Compared with prediction by Cmin alone, this risk score significantly improved reclassification accuracy (IDI=0.050, 95% CI: 0.024-0.076, P<0.001, NRI=0.166, 95% CI: 0.044-0.289, P=0.007). CONCLUSION: The established model in this study is a simplified three-item risk score, which provides a robust tool for the prediction of AKI after receiving vancomycin treatment.
BACKGROUND: Vancomycin is the standard therapy for methicillin-resistant Staphylococcus aureus (MRSA) infection; however, nephrotoxicity happened with a high incidence of 15%~40%. Weighting the risk before receiving vancomycin treatment facilitates timely prevention of nephrotoxicity, but no standardized strategy exists for this purpose. METHODS: A retrospective cohort study was performed. A total of 524 hospitalized patients treated with vancomycin were included in this study. They were divided into derivation cohort (n=341) and externally validation cohort (n=183) according to their admission time. Using univariate and multivariable logistic regression, we identified potential predictors of vancomycin-associated acute kidney injury (AKI) and developed a risk score by plotting nomogram. The predictive performance of this novel risk score was assessed and validated by discrimination and calibration. Besides, the risk score was also compared with existing prediction models according to integrated discrimination index (IDI) and net reclassification index (NRI). RESULTS: The incidence of AKI was 16.1% (55/341) in the derivation cohort and 16.4% (30/183) in the validation cohort. Three factors (vancomycin serum trough concentration, piperacillin/tazobactam and furosemide) were determined as predictors for vancomycin-associated AKI. The established three-item risk score showed a comparable discrimination in both derivation cohort (AUC=0.793, 95% CI: 0.732-0.855) and validation cohort (AUC=0.788, 95% CI: 0.698-0.877). The risk score also demonstrated a good calibration in the derivation cohort (χ 2=6.079, P=0.638>0.05) and validation cohort (χ2=5.665, P=0.686>0.05). Compared with prediction by Cmin alone, this risk score significantly improved reclassification accuracy (IDI=0.050, 95% CI: 0.024-0.076, P<0.001, NRI=0.166, 95% CI: 0.044-0.289, P=0.007). CONCLUSION: The established model in this study is a simplified three-item risk score, which provides a robust tool for the prediction of AKI after receiving vancomycin treatment.
Authors: Jessica A Cintolo-Gonzalez; Danielle Braun; Amanda L Blackford; Emanuele Mazzola; Ahmet Acar; Jennifer K Plichta; Molly Griffin; Kevin S Hughes Journal: Breast Cancer Res Treat Date: 2017-04-25 Impact factor: 4.872
Authors: Bhagyashri Navalkele; Jason M Pogue; Shigehiko Karino; Bakht Nishan; Madiha Salim; Shantanu Solanki; Amina Pervaiz; Nader Tashtoush; Hamadullah Shaikh; Sunitha Koppula; Jonathan Koons; Tanveer Hussain; William Perry; Richard Evans; Emily T Martin; Ryan P Mynatt; Kyle P Murray; Michael J Rybak; Keith S Kaye Journal: Clin Infect Dis Date: 2016-10-20 Impact factor: 9.079
Authors: Nakyung Jeon; Ben Staley; Kenneth P Klinker; Juan Hincapie Castillo; Almut G Winterstein Journal: Int J Antimicrob Agents Date: 2017-05-15 Impact factor: 5.283
Authors: Francesco Costa; David van Klaveren; Stefan James; Dik Heg; Lorenz Räber; Fausto Feres; Thomas Pilgrim; Myeong-Ki Hong; Hyo-Soo Kim; Antonio Colombo; Philippe Gabriel Steg; Thomas Zanchin; Tullio Palmerini; Lars Wallentin; Deepak L Bhatt; Gregg W Stone; Stephan Windecker; Ewout W Steyerberg; Marco Valgimigli Journal: Lancet Date: 2017-03-11 Impact factor: 79.321
Authors: Kang Liu; Xiangzhou Zhang; Weiqi Chen; Alan S L Yu; John A Kellum; Michael E Matheny; Steven Q Simpson; Yong Hu; Mei Liu Journal: JAMA Netw Open Date: 2022-07-01